Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177 Lu or 111 In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).

MLA

Tagawa, Scott T., et al. “Randomized, Double-Blinded Phase II Study of Ketoconazole (Keto), Hydrocortisone (HC), and Anti-PSMA Antibody J591 Labeled with 177 Lu or 111 In in Patients (Pts) with High-Risk Non-Metastatic (Met) Castration-Resistant Prostate Cancer (M0 CRPC).” Journal of Clinical Oncology, vol. 41, Feb. 2023, p. LBA21. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.6_suppl.LBA21.

APA

Tagawa, S. T., Thomas, C., Adra, N., Zakharia, Y., Philips, G., Quinn, D. I., Agarwal, N., Nordquist, L. T., Wulff-Burchfield, E. M., Appleman, L. J., Posadas, E. M., Christos, P. J., Ballman, K. V., Nanus, D. M., & Osborne, J. (2023). Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177 Lu or 111 In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). Journal of Clinical Oncology, 41, LBA21. https://doi.org/10.1200/JCO.2023.41.6_suppl.LBA21

Chicago

Tagawa, Scott T., Charlene Thomas, Nabil Adra, Yousef Zakharia, George Philips, David I. Quinn, Neeraj Agarwal, et al. 2023. “Randomized, Double-Blinded Phase II Study of Ketoconazole (Keto), Hydrocortisone (HC), and Anti-PSMA Antibody J591 Labeled with 177 Lu or 111 In in Patients (Pts) with High-Risk Non-Metastatic (Met) Castration-Resistant Prostate Cancer (M0 CRPC).” Journal of Clinical Oncology 41 (February): LBA21. doi:10.1200/JCO.2023.41.6_suppl.LBA21.